Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people taking Wegovy notice their appetite beginning to change within the first one to four weeks, with measurable weight loss typically appearing by weeks four to eight. Meaningful results — the kind that show up on the scales and in how clothes fit — usually build across the first three to six months, as the dose increases and your body responds. Wegovy (semaglutide) is a prescription-only medicine; a GPhC-registered prescriber assesses your suitability before any treatment begins.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
A question our prescribers hear often: someone starts Wegovy and feels different (less hungry, less interested in large portions) but the number on the scales barely shifts in week one. That is not the medicine failing. The 0.25mg starting dose is chosen specifically to let your digestive system adjust gradually; it is not designed to drive maximum weight loss from day one. Semaglutide works by activating GLP-1 receptors that regulate appetite signals and slow the movement of food through the stomach, but those physiological changes take time to translate into a meaningful calorie deficit, and then for that deficit to show as fat loss rather than water-weight fluctuation.
Most people report their hunger feeling noticeably different somewhere between weeks two and six. Smaller portions feel satisfying. The urge to snack between meals quietens. Those changes are doing the work even before the scales reflect it. If you want a fuller picture of what is happening under the surface in the early weeks, our page on when Wegovy kicks in goes into the mechanism in more detail.
Patience in this phase is not passive, continuing with the lifestyle changes your prescriber recommended alongside treatment is exactly what the trial evidence is built on.
For most people, the first clear evidence of weight loss comes somewhere between weeks four and twelve. This broadly coincides with the first dose increase (from 0.25mg to 0.5mg) which typically happens around week five under the standard titration schedule. Each step up in dose tends to bring a renewed period of appetite reduction, and over several months those steps compound.
The first signs of weight loss on Wegovy vary between individuals: some notice trousers fitting differently before the scales move meaningfully; others see a steady weekly drop from quite early on. Neither pattern is wrong. Body composition, starting weight, activity levels and how closely you follow dietary guidance all influence the pace.
By three months, people who are responding well typically report five to ten percent body weight reduction. By six months, the majority are well into the range the clinical trials demonstrate. The STEP 1 trial, published in the New England Journal of Medicine, showed an average reduction of around 15% body weight over 68 weeks on semaglutide 2.4mg, that is the full treatment period, not just the first few months.
Yes, and understanding this prevents a lot of unnecessary worry. Weight loss on Wegovy rarely follows a neat downward slope. The typical pattern looks more like a stepped descent: progress, a plateau, then further progress after the next dose increase or a period of consistency in habits.
Plateaus are not treatment failure. They reflect the body's natural tendency to adapt its energy expenditure as weight falls, a well-documented phenomenon, not a Wegovy-specific quirk. The pace of weight loss on Wegovy tends to be fastest in the first six months, then gradually moderates as you approach a new equilibrium.
The highest licensed dose (2.4mg weekly, and from April 2026 a 7.2mg option for some patients) represents the maintenance phase. At that point, the goal shifts slightly from active loss to holding a lower weight and protecting metabolic health. Thinking about a private prescription for Wegovy involves understanding these long-term dynamics; for context on what Wegovy costs privately, that page lays out the market clearly.
Starting weight plays a role: someone with a higher BMI may see a larger absolute number on the scales early on, even if the percentage is similar. Metabolic health, hormonal factors, sleep quality and how consistently you follow dietary guidance all contribute too. Strength training alongside treatment tends to preserve lean muscle as fat is lost, which matters for body composition and long-term weight maintenance.
The dose you are on at any given moment is probably the biggest single factor. You cannot be on the full therapeutic dose until the titration schedule has run its course, typically four to five months. Comparing your week-four results to someone's six-month results is not a fair test of whether Wegovy is working for you. For a broader look at the timeline across the full treatment period, how long it takes to lose weight on Wegovy covers the longer arc in detail.
Keep your pen stored in the fridge door (a practical habit that makes it easy to check before your weekly injection day) and if you have any questions about your progress or how you are tolerating treatment, our team is reachable seven days a week. You can also read about how long Wegovy takes to work for a clinical perspective on the pharmacology. If you are considering starting, a free consultation with our prescribers is the first step, they review every application personally, the same day it arrives.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.